

CORRECTION

Open Access



Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Qian Jiang¹, Zongru Li¹, Yazhen Qin¹, Weiming Li², Na Xu³, Bingcheng Liu⁴, Yanli Zhang⁵, Li Meng⁶, Huanling Zhu⁷, Xin Du⁸, Suning Chen⁹, Yang Liang¹⁰, Yu Hu², Xiaoli Liu³, Yongping Song⁵, Lichuang Men¹¹, Zi Chen¹¹, Qian Niu¹¹, Hengbang Wang¹¹, Ming Lu¹², Dajun Yang^{13,14}, Yifan Zhai^{11,12} and Xiaojun Huang^{1,15,16,17*}

Correction to: *Journal of Hematology & Oncology* (2022) 15:113
<https://doi.org/10.1186/s13045-022-01334-z>

The original article [1] contained three erroneous citations and other minor typesetting errors in the text which have since been amended.

Author details

¹National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, China. ²Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China. ³Department of Hematology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou N Ave, Baiyun, Guangzhou 510515, Guangdong Province, China. ⁴State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China. ⁵Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, Henan, China. ⁶Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science

and Technology, Wuhan 430022, Hubei, China. ⁷Department of Hematology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Wuhou District, Chengdu 610000, Sichuan, China. ⁸Division of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, 3002 Sungang W Rd, Futian District, Shenzhen 518000, Guangdong Province, China. ⁹National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. ¹⁰State Key Laboratory of Oncology in South China, Department of Hematologic Oncology, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, Guangdong Province, China. ¹¹Guangzhou Healthquest Pharma Co. Ltd., Room F314, GIBI, No. 3 Lanyue Road, Guangzhou 510663, China. ¹²Ascentage Pharma Group Inc, 800 King Farm Blvd Suite 300, Rockville, MD 20850, USA. ¹³Ascentage Pharma (Suzhou) Co., Ltd, 218 Xinghu St, Bldg B7, 7Th Floor, Suzhou Industrial Park, Suzhou 215000, Jiangsu, China. ¹⁴State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou 510060, Guangdong Province, China. ¹⁵Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, China. ¹⁶Peking-Tsinghua Center for Life Sciences, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, China. ¹⁷Academy for Advanced Interdisciplinary Studies, Peking University, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, China.

The original article can be found online at <https://doi.org/10.1186/s13045-022-01334-z>.

*Correspondence: huangxiaojun@bjmu.edu.cn

¹ National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, China
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Published online: 31 October 2022

Reference

1. Jiang, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. *J Hematol Oncol.* 2022;15:113. <https://doi.org/10.1186/s13045-022-01334-z>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.